Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Zsuzsanna McMahan¹, Srinivas Puttapaka², Livia Casciola-Rosen³, Timothy Kaniecki³, Laura Gutierrez³, Su Hong MIng², Philippa Seika² and Subhash Kulkarni⁴, ¹UT Health Houston, Houston, TX, ²BIDMC/Harvard, Boston, MA, ³Johns Hopkins University, Baltimore, MD, ⁴BIDMC, Boston, MA
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
Abstract Number: 2414 • ACR Convergence 2025
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Alice Horisberger¹, Emily Oakes², Eilish Dillon³, Ifeoluwakiisi Adejoorin², Julia Caldropoli³, Kathryne Marks², Takanori Sasaki³, Farbod Moghaddam⁴, Paul Sciore⁵, Marvin J. Fritzler⁶, Deepak Rao², May Choi⁷ and Karen H. Costenbader⁸, ¹Lausanne University Hospital, University of Lausanne, Laussane, Switzerland, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴University of Calgary, Calgary, Canada, ⁵MitogenDx, Calgary, AB, Canada, ⁶MitognDx, Calgary, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Up to a third of those with suspected SLE progress to definite SLE; however, reliable predictive markers for disease progression remain unknown. Previously, we…
Abstract Number: 2027 • ACR Convergence 2025
Development of a multi-disease panel for autoimmune diseases
Charlotta Preger, Maria Aspenberg, Metta Berenpas, Peter Nilsson and Elisa Pin, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…
Abstract Number: 1488 • ACR Convergence 2025
Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
Jessica Dai¹, Peter Izmirly², Jill Buyon³ and H Michael Belmont⁴, ¹New York University Grossman School of Medicine, Tenafly, NJ, ²New York University Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Anti-dsDNA antibodies are a key diagnostic marker of systemic lupus erythematosus (SLE), often associated with active disease. Its presence is detected using various commercial…
Abstract Number: 0953 • ACR Convergence 2025
NMDAR Autoantibody-Induced Neuronal Damage in the Amygdala Mediates Mood and Anxiety Disorders in a Model of Neuropsychiatric Lupus
Rachel Weissman-Tsukamoto¹, Bruce Volpe¹, Zaide Ibic¹, Kaitlin Carroll², An Vo¹, Czeslawa Kowal¹ and Betty Diamond³, ¹Feinstein Institute of Molecular Medicine, Manhasset, NY, ²Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease characterized by aberrant production of autoantibodies and chronic inflammation. Up to 80% of individuals with…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0296 • ACR Convergence 2025
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
maria Casal-Dominguez¹, Iago Pinal Fernandez², Katherine Pak², Travis Kinder¹, Jon Musai¹, Ana Matas-Garcia³, Gloria Garrabou⁴, Iban aldecoa⁵, Albert Selva-O´callaghan⁶, José Milisenda⁷ and Andrew Mammen⁸, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, Spain, ⁴Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, ⁵Pathology, Neurological Tissue Bank. Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain., Barcelona, ⁶Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain, Barcelona, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIH, Bethesda, MD
Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among…
Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Maria Cecilia Ramello², Agustin Plasencia², Jordan Anderson², Tobias Green², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Raj Sengupta¹, Anthony Marotta², Walter P. Maksymowych³, Charlotte Cavill⁴, Stephen Bleakley² and Norma Biln⁵, ¹Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ²Augurex Life Sciences Corp, Vancouver, BC, Canada, ³Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁴Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁵Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…
Abstract Number: 2398 • ACR Convergence 2025
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Jason Sillitoe¹, Ewa Fiorentino-Rozek², Gerber Gomez³, Christian Fischer³ and Caroline Wilson¹, ¹North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ²Clinical Affairs, AliveDx Suisse SA, Eysins, Vaud, Switzerland, ³Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…
Abstract Number: 1331 • ACR Convergence 2025
Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Changes in serum cholesterol loading capacity (CLC) on macrophages were linked to coronary plaque progression in rheumatoid arthritis (RA). Inflammation, LDL oxidation and autoantibodies…
Abstract Number: 0942 • ACR Convergence 2025
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
Jennifer Nicholson¹, Maria Ossa-Echeverri¹, Arpitha Haranahalli Shivarudrappa¹, Mark Lusco¹, Maria de la Luz Garcia-Hernandez², John Looney¹, Jennifer Anolik³ and Javier Rangel-Moreno¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Though immune targeted therapies have improved outcomes in lupus nephritis, a significant number of patients experience renal damage and even progression to end stage…
Abstract Number: 0860 • ACR Convergence 2025
Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
Maria Efthymiou¹, Ibrahim Tohidi-Esfahani², Veronica Venturelli¹, Maria Tektonidou³, Vittorio Pengo⁴, Diana Parades-Ruiz⁵, Ware Branch⁶, Maria Gerosa⁷, Cecilia Nalli⁸, Esther Rodriguez Almaraz⁹, Michelle Petri¹⁰, Ricard Cervera¹¹, Olga Amengual¹², Danieli Andrade¹³, Rohan Willis¹⁴, Maria Laura Bertolaccini¹⁵, Doruk Erkan¹⁶ and Hannah Cohen¹⁷, ¹University College London, London, United Kingdom, ²University of Sydney, Syndey, Australia, Sydney, Australia, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵Biobizkaia Health Research Institute, Barakaldo, Spain, Barakaldo, Spain, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷University of Milan, Milano, Italy, ⁸ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁹Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Hospital Clinic Barcelona, Barcelona, Spain, ¹²Hokkaido University Graduate School of Medicine, Sapporo, Japan, Sapporo, Japan, ¹³University of Sao Paulo, São Paulo, São Paulo, Brazil, ¹⁴University of Texas Medical Branch, Galveston, TX, ¹⁵King's College London, London, United Kingdom, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Dysregulation in the protein C anticoagulant pathway, more specifically acquired resistance to activated protein C (APCr) and antibodies against protein C (anti-PC), has been…
Abstract Number: 0281 • ACR Convergence 2025
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Anja Srpcic¹, Manca Ogric¹, Sasa Cucnik¹, Sergej Pirkmajer², Katja Lakota¹ and Katja Perdan Pirkmajer¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…

1
2
3
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].